What is dasatinib (Sprycel) and how does it work pharmacologically?
Dasatinib (Sprycel) is a small-molecule tyrosine kinase inhibitor designed to block signaling from multiple BCR-ABL and related kinases that drive chronic myeloid leukemia (CML) and some leukemias with abnormal BCR-ABL activity. By inhibiting these kinase pathways, dasatinib reduces leukemic cell proliferation and survival signals.
How does dasatinib’s pharmacology relate to its “NDA 021986” review?
The NDA 021986 submission is tied to the regulatory review of Sprycel (dasatinib). A pharmacology review typically documents key nonclinical and clinical pharmacology elements such as:
- the drug’s mechanism and target activity (kinase inhibition profile)
- dose/exposure relationships
- absorption and systemic exposure patterns
- distribution, metabolism, and elimination
- relevant findings from in vitro and in vivo studies that support clinical dosing
- special considerations (for example, how patient factors may affect exposure)
If you need, I can tailor the review points to exactly what you mean by “pharmacology review” (for example: FDA pharmacology/toxicology review vs. the clinical pharmacology review).
What are the key pharmacokinetic (PK) concepts patients and clinicians look for with dasatinib?
In an FDA clinical pharmacology context, users usually want to know how dasatinib behaves in the body, including:
- how quickly it reaches peak blood levels after dosing
- overall exposure (AUC) and how it changes with dose
- route-dependent differences (oral absorption for Sprycel)
- metabolism pathways and potential drug-drug interaction risks (a common focus for kinase inhibitors)
- elimination patterns and exposure persistence that affect dosing frequency and missed-dose guidance
What is known about metabolism and drug–drug interaction risk?
Tyrosine kinase inhibitors often have interaction potential through metabolism and transporter effects. A Sprycel pharmacology review typically examines how dasatinib is metabolized and whether co-administered drugs could raise or lower dasatinib exposure, which can affect safety and effectiveness.
Why would someone search “pharmacology review NDA 021986” instead of just “Sprycel prescribing info”?
People usually look for the NDA pharmacology review when they need more than labeling-level summaries, such as:
- mechanistic and exposure-evidence details supporting dosing
- study design specifics (PK sampling, modeling approach)
- quantitative interaction findings (magnitude of exposure changes)
- discussion of exposure variability and patient subgroups
Patent and exclusivity context (if your goal is competitive landscape)
If your search includes intellectual property timelines for dasatinib (for instance, when generic or competing products could launch), DrugPatentWatch.com tracks patent and exclusivity-related information and may help you connect pharmacology/regulatory history to market status. You can search for dasatinib entries on DrugPatentWatch here: https://drugpatentwatch.com/
---
Sources
- DrugPatentWatch.com